Profusa Platform Technology | Injectable Hydrogel Biosensors for Continuous Monitoring

A Platform 10 Years and
$100M+ in the Making

Profusa's biologically integrated sensor system redefines what continuous monitoring can achieve — delivering clinical-grade biochemical data from inside the body for up to 9+ months from a single injectable sensor.

System Architecture

Three Components.
One Integrated System.

01
Injectable Hydrogel Microsensor

A novel, biologically compatible hydrogel microsensor injected subcutaneously via standard hypodermic needle. Operates for 9+ months without replacement. Eliminates foreign body rejection — the key barrier for long-duration CGM and oxygen sensors.

< 1mm diameter
9+ months functional life
No surgical removal required
02
Reusable Optical Reader & Data Management

A low-cost, reusable optoelectronic reader worn on the body. Communicates sensor data via Bluetooth to smartphone app and Profusa Cloud. Consumes only an on-body adhesive — dramatically reducing per-patient cost.

Reusable device
Bluetooth connected
iOS & Android compatible
03
Personalized Clinical Insights (AI Platform)

Machine learning algorithms account for individual tissue variation to deliver continuously accurate measurements. NVIDIA technology backbone powers data processing. Planned physician portal links real-time biochemistry to EMR and clinical literature.

NVIDIA AI backbone
Cloud-based
EMR integration roadmap
AI & DATA SCIENCE

AI-Adaptive. Personalized. Always Learning.

The Lumee™ platform's machine learning layer sets it apart from any conventional biosensor technology on the market.

Algorithms account for individual variations in tissue composition to maintain continuous measurement accuracy over months — without recalibration
Multiple physical variables and fluctuations are processed in real-time to generate accurate oxygen and glucose readings
Real-time comparison across large data sets enables population-level clinical insights
NVIDIA technology backbone selected for best-in-class AI processing capability
Planned physician portal links real-time biochemistry data with EMR records and published clinical literature
Machine learning distinguishes between privacy-protected and useable clinical data across any network
Glucose MARD (clinical trial)
10–12%
Sensor functional life
270+ days
Paired reference data points
>18,000
AI backbone partner
NVIDIA
Analytes in development
O₂ · Glucose · Lactate · CO₂
85
Global patents granted or pending
~$100M+
Invested
$30M
DARPA + NIH Non-Dilutive
~10+ yrs
of development
Core Innovation

The Fundamental Problem We Solved

Every existing biosensor — from CGM devices to pulse oximeters — struggles with one core biological challenge: the body's foreign body response attacks and degrades implanted sensors within days or weeks. Profusa solved this by engineering a hydrogel material that the body treats as its own tissue. The result is a sensor that lives inside the body for 9+ months, continuously transmitting clinical-grade data.

Conventional Sensors vs. Lumee™
Sensor Life
7–14 days
270+ days
🔪
Deployment
Insertion device / surgery
Standard needle injection
💰
Annual Cost
Up to $7,000/yr
~$900/yr
🔄
Recalibration
Frequent
AI-adaptive, none
👥
Patient Population
T1D intensive only
T1D through prediabetes
For Investors
Learn How the Platform Translates to Revenue
View Pipeline & Financials →
For Clinicians
See the Clinical Evidence Behind the Technology
View Clinical Data →